Search





Search





Markets
/
Stocks
/
cosm
/

Cosmos Health Inc

COSM

Add to Watchlist

0.210USD

+0.010+4.95%

Close 07-31 16:00（ET）Quotes delayed by 15 min

8.62MMarket Cap

LossP/E TTM

Cosmos Health Inc

0.210

+0.010+4.95%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

+4.95%

5 Days

+5.05%

1 Month

+13.70%

6 Months

-56.29%

Year to Date

-57.83%

1 Year

-77.29%

Key Figures

0.200Open

0.216High

5.02MVolume

LossP/E TTM

--P/E Dynamic

--Dividend TTM

12.23%Turnover Ratio

0.200Prev. Close

0.195Low

761.90KTurnover

LossP/E Static

0.43P/B

0.00%Div Yield TTM

-35.35%ROA

1.32052wk High

1.38Volume Ratio

-22.38MNet Profit

41.07MShares

-0.6602EPS TTM

4.17Beta

-92.33%ROE

0.24652wk Low

10.54%Amplitude

5.76%Gross Margin

8.62MMarket Cap

-2.26Reward/Risk

6.90%Risk Rate

TradingKey Stock Score of Cosmos Health Inc

Currency: USD Updated: 2026-07-31

Key Insights

Cosmos Health Inc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 112 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as , with the highest price target at 4.50.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cosmos Health Inc's Score

Industry at a Glance

Industry Ranking

112 / 155

Overall Ranking

308 / 4281

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Cosmos Health Inc Highlights

StrengthsRisks

Cosmos Health Inc. is a diversified, vertically integrated global healthcare company. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life, Mediterranation, bio-bebe, C-Sept and C-Scrub. Through its subsidiary Cana Laboratories S.A., it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. It also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and over-the-counter (OTC) medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the United Kingdom. It also has research and development (R&D) partnerships targeting health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of patented nutraceuticals, specialized root extracts, proprietary complex generics, and OTC products.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 22.28% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 65.27M.

Overvalued

The company’s latest PE is -0.33, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 1.44M shares, decreasing 55.80% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 6.18.